Management

Barry Quart, Pharm.D.
Chief Executive Officer and Director

Robert Rosen
President and Director

Mark Gelder, M.D.
Senior VP, Chief Medical Officer

Michael Adam, Ph.D.
Senior VP, Regulatory Affairs and Quality

Paul Marshall
Senior VP, Technical Operations

Thomas Ottoboni, Ph.D.
Senior VP, Pharmaceutical and Preclinical Research and Development

Brian Drazba
VP, Finance and Chief Financial Officer

Esmé Smith
VP, General Counsel and Secretary


Barry Quart, Pharm.D.
Chief Executive Officer and Director

Barry D. Quart, Pharm.D. joined Heron Therapeutics in May 2013 as Chief Executive Officer and has served as a member of our Board of Directors since June 2012. Dr. Quart was most recently President and Chief Executive Officer of Ardea Biosciences, Inc., where he served in that role since the company’s founding in December 2006 until May 2013. Ardea was acquired by AstraZeneca PLC for $1.26 billion in June 2012. Prior to Ardea, Dr. Quart was with Pfizer,Inc. as Senior Vice President of Pfizer Global Research and Development and the Director of Pfizer’s La Jolla Laboratories, where he was responsible for approximately 1,000 employees and an annual budget of almost $300 million. Prior to Pfizer’s acquisition of the Warner-Lambert Company, Dr. Quart was President of Research and Development at Agouron Pharmaceuticals, Inc., a division of the Warner-Lambert Company. Agouron was acquired by Warner-Lambert for $2.1 billion in 1999. Dr. Quart joined Agouron in 1993 and was instrumental in the development and registration of Viracept® (nelfinavir), which went from the lab bench to new drug application approval in 38 months. Dr. Quart received his Pharm.D. degree from the University of California, San Francisco.

Back to top

Robert Rosen
President and Director

Robert H. Rosen joined Heron Therapeutics as Senior Vice President and Chief Commercial Officer in October 2012 and was appointed as President in May 2013. Mr. Rosen has also served as a member of our Board of Directors since July 2012. Prior to joining Heron Therapeutics, Mr. Rosen was Managing Partner of Scotia Nordic LLC. From April 2011 to March 2012, Mr. Rosen served as Senior Vice President of Global Commercial Operations at Dendreon Corporation. From 2005 to 2011, he served as Global Head of Oncology at Bayer HealthCare Pharmaceuticals, where he was responsible for the development of the Global Oncology Business Unit for regions that included the Americas, Europe, Japan, and Asia Pacific. During his tenure at Bayer, he led the launch of Nexavar® (sorafanib) for the treatment of renal cell carcinoma and hepatocellular carcinoma. Nexavar’s worldwide sales in 2011 were $1.0 billion. He also led premarket activities for Stivarga® (regorafenib) for gastrointestinal stromal tumors and colon cancer and Alpharadin® (now called Xofigo )(radium 223 dichloride) for prostate cancer. From 2002 to 2005, Mr. Rosen was Vice President of the Oncology Business Unit at Sanofi-Synthèlabo, where he was responsible for the development of Sanofi’s U.S. oncology business and the launch of Eloxatin® (oxaliplatin) for colon cancer. Eloxatin U.S. sales in 2005, its third full year on the market, were $1.1 billion, ranking it among the industry’s most successful oncology drug launches. Mr. Rosen received his B.S. degree in pharmacy from Northeastern University.

Back to top

Mark Gelder, M.D.
Senior VP, Chief Medical Officer

Mark S. Gelder, M.D. joined Heron Therapeutics as Senior Vice President and Chief Medical Officer in December 2012. From October 2007 to December 2011, Dr. Gelder was the Vice President and Global Head of Medical Affairs and Pharmacovigilance at GE Healthcare Medical Diagnostics. During his tenure at GE Healthcare, he led the global medical affairs strategy, including preparation and execution of medical launch plans. He was also responsible for global Phase IV and other post-approval commitment studies. Prior to GE Healthcare, Dr. Gelder was the Vice President of Global Medical Affairs of Oncology for Bayer HealthCare Pharmaceuticals, and was responsible for the global medical strategy supporting the launch of Nexavar® (sorafanib), Stivarga® (regorafenib), and Alpharadin® (now called Xofigo )(radium 223 dichloride) global programs. Dr. Gelder was also the Global Therapeutic Area Director of Oncology at Wyeth from December 2005 to October 2007, with a focus on the commercial launch of Torisel® (temsirolimus). Earlier in his career, Dr. Gelder held roles of increasing responsibility at Pfizer, Inc., working on Sutent® (sunitinib malate), and was also a practicing gynecologic oncologist in both the academic and private sectors. Dr. Gelder received his B.S. degree in biochemistry from Colgate University, and his M.D. degree from the University of Virginia’s School of Medicine.

Back to top

Michael Adam, Ph.D.
Senior VP, Regulatory Affairs and Quality

Michael A. Adam, Ph.D. joined Heron Therapeutics as Senior Vice President of Regulatory Affairs and Quality in May 2011. Dr. Adam has been working with the Company as a consultant since July 2010 and brings over 25 years of drug development and pharmaceutical operations experience to the organization. He was most recently Senior Vice President of pharmaceutical operations at Spectrum Pharmaceuticals, Inc., from October 2008 through June 2010, where he oversaw CMC development, quality assurance and manufacturing. Prior to Spectrum, from March 2006 through February 2007, Dr. Adam served as Vice President of Drug Development Operations at Anadys Pharmaceuticals, Inc., where he was responsible for regulatory affairs, quality assurance, pharmaceutical development, manufacturing and project management. He also has held senior positions with Pfizer, Inc., Agouron Pharmaceuticals, Inc. and Bristol-Myers Squibb Company. Dr. Adam earned his Ph.D. degree in organic chemistry at the Massachusetts Institute of Technology.

Back to top

Paul Marshall
Senior VP, Technical Operations

Paul G. Marshall joined Heron Therapeutics as Senior Vice President of Technical Operations in November 2013. Mr. Marshall has 27 years of experience in the development and commercialization of pharmaceutical products, including manufacturing and supply chain responsibility for 14 approved drugs and biologics, three of which achieved blockbuster (sales >$1B) status. Since 2006, Mr. Marshall held ascending executive positions within Amylin Pharmaceuticals, Inc., including Senior Vice President of Operations. Prior to Amylin, Mr. Marshall held executive manufacturing positions at Amgen, Inc. and Baxter International. He has held management positions at Creative BioMolecules, Welgen Manufacturing Partnership (now Amgen, Rhode Island), Repligen Corporation and Damon Biotech. Mr. Marshall received his B.S. and M.S. degrees in biology from the University of Massachusetts at Dartmouth and completed three years of post-graduate work concentrating in hematology and coagulation research at Brown University.

Back to top

Thomas Ottoboni, Ph.D.
Senior VP, Pharmaceutical and Preclinical Research and Development

Thomas B. Ottoboni, Ph.D. joined Heron Therapeutics as Vice President of Pharmaceutical Development in March 2012 and was appointed to his current role in July 2014. Most recently, Dr. Ottoboni was Vice President of Research and Development at Talima Therapeutics, from 2010 to 2011, where he worked on the development of a drug delivery implant to treat onychomycosis. Dr. Ottoboni also served as Executive Vice President of Strategy and Operations at POINT Biomedical Corp. from 1996 through 2008, where he developed several imaging and drug delivery systems. Dr. Ottoboni served as Manager of Systems Development and Drug Delivery Research for InSite Vision, Inc. from 1994 through 1996, where he developed ophthalmic pharmaceutical delivery systems, and prior to that, he served as Director of Drug Delivery at Vitaphore Corp. Dr. Ottoboni is an inventor on more than 19 U.S. patents in organic and macromolecular chemistry. He received his B.S. degree in chemistry and his Ph.D. in organic chemistry from the University of California, Berkeley.

Back to top

Brian Drazba
VP, Finance and Chief Financial Officer

Brian G. Drazba joined Heron Therapeutics as Vice President of Finance and Chief Financial Officer in October 2013 and brings nearly 30 years of financial management experience to Heron Therapeutics. Most recently, he was Vice President of Finance and Chief Accounting Officer for ISTA Pharmaceuticals Inc. where he led the financial reporting, analysis, and tax functions. From 1992 to 2006, Mr. Drazba held positions of increasing responsibility within Insight Health Corp., including Senior Vice President and Chief Accounting Officer. Prior to his tenure at Insight Health, Mr. Drazba was employed by Arthur Andersen & Co. He is a licensed Certified Public Accountant in California and holds a B.A. degree in accounting from the University of San Diego.

Back to top

Esmé Smith
VP, General Counsel and Secretary

Esmé C. Smith joined Heron Therapeutics in as Vice President, General Counsel and Secretary in August 2014. Prior to joining the Company full-time, Ms. Smith advised Heron on legal matters and brings over 15 years of industry and legal experience to her role. From July 2009 through March 2012, Ms. Smith served as Vice President, Deputy General Counsel and Assistant Secretary at Dendreon Corporation, where she had a critical role overseeing the company’s legal responsibilities during its transition from clinical-stage to a global, commercial company. Prior to Dendreon, Ms. Smith was a Partner with the global law firm Jones Day in the Firm’s Mergers & Acquisitions and Capital Markets groups. Ms. Smith received a B.A. degree from the University of California, Santa Barbara and her J.D. cum laude from Loyola Law School in Los Angeles.

Back to top